Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan (VRA)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2013 by University of Oxford
Sponsor:
Collaborators:
National Malaria and Leishmaniasis Control Program, Afghanistan
Mahidol University
Information provided by (Responsible Party):
University of Oxford
ClinicalTrials.gov Identifier:
NCT01178021
First received: August 6, 2010
Last updated: August 27, 2013
Last verified: August 2013
  Purpose

This is an open label two-arm randomized prospective study of two treatments for P. vivax malaria. Patients meeting study inclusion criteria will be enrolled and allocated either chloroquine alone or chloroquine plus primaquine (0.25mg/kg/day for 14 days). Patients will be followed-up for 1 year, with clinical and laboratory examinations at each visit. Patients with recurrent P. vivax infection will be treated with the same medication as initially randomized unless contraindicated. Recurrences in the two arms will be compared to estimate the risk of and mean duration to relapse, classify the relapse pattern as early or late relapse and to estimate the efficacy and safety of the study drugs.

Polymerase Chain Reaction (PCR) analysis will be used as far as possible help to distinguish between relapse and re-infection. Samples for chloroquine pharmacokinetic analysis will be collected on day 7 from each study subject as well as on the day of recurrence if within 8 weeks of chloroquine


Condition Intervention Phase
Vivax Malaria
Drug: Chloroquine
Drug: Chloroquine/Primaquine
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan

Resource links provided by NLM:


Further study details as provided by University of Oxford:

Primary Outcome Measures:
  • Secondary vivax attack [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    Completion of the 1-year (± 1 month) follow-up period without secondary vivax attack


Secondary Outcome Measures:
  • secondary vivax attack [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Completion of 6-months (± 1 month) follow-up without secondary vivax attack

  • G6PD prevalence [ Time Frame: Time of enrollment ] [ Designated as safety issue: No ]
    G6PD status of patients

  • Recurrence [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    Time to first recurrence, median time between episodes of vivax infections and total number of episodes in the follow up period

  • Days of illness, haematocrit [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    Overall number of days of illness and haematocrit below 30%

  • Chloroquine levels [ Time Frame: Day 7 ] [ Designated as safety issue: No ]
    Whole blood chloroquine level at day 7 and any day of recurrence of Plasmodium vivax malaria

  • Adverse events [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
    Adverse event profiles of chloroquine and primaquine


Estimated Enrollment: 600
Study Start Date: January 2010
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Chloroquine
Standard arm
Drug: Chloroquine
Chloroquine 10 mg/kg on day 0 & 1 and 5mg/kg on day 2
Experimental: Chloroquine/Primaquine
Chloroquine combined with primaquine
Drug: Chloroquine/Primaquine
Chloroquine 10 mg/kg on day 0 & 1 and 5mg/kg on day 2 Primaquine (if given) 0.25mg/kg/day for 14 days

Detailed Description:

Globally more than 100 countries are endemic of malaria and about 60% of world population are at risk of getting the infection while around 10% are harboring malaria parasite in their blood stream. Of the four species of plasmodium that infect humans, Plasmodium vivax is responsible for 50% of all malaria cases outside Africa, and is endemic in the Middle East, Asia and Western Pacific, with a lower prevalence in Central and South America a common cause of malaria in many tropical and subtropical regions. Conventional control methods are rather inefficient for preventing transmission of this species of malaria. This is partly due to the persistence of the infectious reservoir, which take the form of latent hypnozoites in the liver, producing recurrent relapses and opportunities for new transmission for several years after initial infection.

Primaquine (PQ) is the only available drug regimen which can eliminate the persisting liver stages (hypnozoites) of P. vivax,but its use for 14 days is ineffective to prevent relapses at 15 mg daily dose (0.25mg/kg) in Southeast Asia and in Brazil, and at a higher dose of 22.5 mg daily in the Southwest Pacific. Due to high relapse rates, a primaquine regimen of 30 mg daily (0.5 mg/kg) for 14 d is now widely recommended for glucose-6-phosphate dehydrogenase (G6PD) normal patients.

P.vivax is the predominant species in Pakistan and eastern Afghanistan. In this area G6PD deficiency is a common trait (7% in Pakistani and 14% in Afghan Pashtoon respectively). However facilities to test for G6PD deficiency are not available and hence routine administration of primaquine is not recommended in national guidelines because of the risk of severe haemolysis in those who cannot be tested.

Several national malaria programmes in Asia have adopted a truncated 5-day course of PQ for vivax malaria to reduce the risk of haemolysis to reasonable levels and to increases compliance rates. Recently this has been documented as being ineffective at reducing relapse rates amongst Afghan refugees in Pakistan while a supervised 14 day course can significantly reduce the frequency of second and third episodes of disease. This is also confirmed by a study in India. Use of the 14 day course is only recommended where the G6PD status of the individual is known, and, currently, where compliance with the full course can be assured. However supervision of patients for 14 day post presentation is seldom feasible in the majority of settings where vivax malaria predominates. Therefore the supposition that patients in a low literacy population will not comply with a 14 day course of treatment in the absence of supervision needs to be confirmed under normal operational conditions. Compliance in taking the drug cannot be monitored by direct observation or by chemical assay of residues in the blood because such interference may, in itself, affect compliance.

  Eligibility

Ages Eligible for Study:   6 Months and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adults and children >6 months
  • Negative pregnancy test in women at risk of pregnancy
  • Microscopic diagnosis of Plasmodium vivax mono-infection (>200/µl asexual forms)
  • Axillary temperature ≥37.5°C or oral/rectal temperature ≥38°C or history of fever within the last 24 hours
  • Ability to swallow oral medication
  • Participant (or parent/guardian if <18 years old) is willing and able to give written informed consent
  • Ability (in the investigator's opinion) and willingness of patient or parent/guardian to comply with all study requirements

Exclusion Criteria:

  • Severe malaria (see WHO definition)
  • Patients with microscopic diagnosis of co-infection with Plasmodium falciparum
  • Haemoglobin concentration <8g/dl
  • Presence of any condition which in the judgement of the investigator would place the subject at undue risk or interfere with the results of the study e.g. other acute febrile conditions or chronic disease
  • Pregnancy or lactation
  • History or phenotypic test compatible with severe G6PD deficiency
  • History of hypersensitivity to any of the drugs being tested
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01178021

Contacts
Contact: Phaik Yeong Cheah, PhD phaikyeong@tropmedres.ac
Contact: Charlie Woodrow, MBBS charlie@tropmedres.ac

Locations
Afghanistan
Provincial Malaria Control Centers (MRC) Recruiting
Maimana, Faryab, Afghanistan
Contact: Ghulam Rahim Awab, MD       awabgr@yahoo.com   
Principal Investigator: Ghulam Rahim Awab, MD         
Provincial Malaria Control Centers (MRC) Recruiting
Jalalabad, Afghanistan
Contact: Ghulam Rahim Awab, MD         
Principal Investigator: Ghulam Rahim Awab, MD         
Provincial Malaria Control Centers (MRC) Recruiting
Kunduz, Afghanistan
Contact: Ghulam Rahim Awab, MD         
Principal Investigator: Ghulam Rahim Awab, MD         
Sponsors and Collaborators
University of Oxford
National Malaria and Leishmaniasis Control Program, Afghanistan
Mahidol University
Investigators
Principal Investigator: Ghulam Rahim Awab, MD Mahidol Oxford Research Unit
  More Information

No publications provided

Responsible Party: University of Oxford
ClinicalTrials.gov Identifier: NCT01178021     History of Changes
Other Study ID Numbers: BAKMAL0903
Study First Received: August 6, 2010
Last Updated: August 27, 2013
Health Authority: Afghanistan: Ministry of Public Health

Keywords provided by University of Oxford:
malaria
vivax
relapse

Additional relevant MeSH terms:
Malaria
Malaria, Vivax
Protozoan Infections
Parasitic Diseases
Chloroquine
Chloroquine diphosphate
Primaquine
Amebicides
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Antimalarials
Antirheumatic Agents
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Filaricides
Antinematodal Agents
Anthelmintics
Central Nervous System Agents

ClinicalTrials.gov processed this record on September 30, 2014